FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315473447> ?p ?o ?g. }

• W4315473447 abstract "In the phase 3 POLARIX study (NCT03274492), polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with similar safety in previously untreated diffuse large B-cell lymphoma. Patients were randomized 1:1 to 6 cycles of Pola-R-CHP or R-CHOP plus 2 cycles of rituximab alone. For registration of POLARIX in China, consistency of PFS in an Asia subpopulation (defined as ≥50% of the risk reduction in PFS expected in the global population) was evaluated. Overall, 281 patients were analyzed: 160 patients from Asia in the intent-to-treat (ITT) population of the global study and 121 from an ITT China extension cohort. Of these, 141 were randomized to Pola-R-CHP and 140 to R-CHOP. At data cut-off (June 28, 2021; median follow-up 24.2 months), PFS met the consistency definition with the global population and was superior with Pola-R-CHP versus R-CHOP (hazard ratio 0.64; 95% confidence interval [CI], 0.40-1.03). Two-year PFS was 74.2% (95% CI, 65.7-82.7) and 66.5% (95% CI, 57.3-75.6) with Pola-R-CHP and R-CHOP, respectively. Safety was comparable between Pola-R-CHP and R-CHOP, including rates of grade 3-4 adverse events (AEs; 72.9% vs 66.2%, respectively), serious AEs (32.9% vs 32.4%), grade 5 AEs (1.4% vs 0.7%), AEs leading to study treatment discontinuation (5.0% vs 7.2%), and any-grade peripheral neuropathy (44.3% vs 50.4%). These findings demonstrate consistent efficacy and safety of Pola-R-CHP versus R‑CHOP in the Asian and global populations in POLARIX." @default.
• W4315473447 created "2023-01-11" @default.
• W4315473447 creator A5000406804 @default.
• W4315473447 creator A5000432967 @default.
• W4315473447 creator A5001892235 @default.
• W4315473447 creator A5002329460 @default.
• W4315473447 creator A5003078312 @default.
• W4315473447 creator A5003656187 @default.
• W4315473447 creator A5004358361 @default.
• W4315473447 creator A5004550999 @default.
• W4315473447 creator A5006621752 @default.
• W4315473447 creator A5006822602 @default.
• W4315473447 creator A5010046270 @default.
• W4315473447 creator A5012675709 @default.
• W4315473447 creator A5013007045 @default.
• W4315473447 creator A5014614303 @default.
• W4315473447 creator A5018450513 @default.
• W4315473447 creator A5019218337 @default.
• W4315473447 creator A5019659276 @default.
• W4315473447 creator A5026641386 @default.
• W4315473447 creator A5028596968 @default.
• W4315473447 creator A5034694073 @default.
• W4315473447 creator A5047640708 @default.
• W4315473447 creator A5058521062 @default.
• W4315473447 creator A5061466414 @default.
• W4315473447 creator A5063300954 @default.
• W4315473447 creator A5064319201 @default.
• W4315473447 creator A5072617729 @default.
• W4315473447 creator A5076088179 @default.
• W4315473447 creator A5076570353 @default.
• W4315473447 creator A5084148942 @default.
• W4315473447 creator A5087038882 @default.
• W4315473447 creator A5090013547 @default.
• W4315473447 date "2023-01-10" @default.
• W4315473447 modified "2023-10-16" @default.
• W4315473447 title "Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the Phase 3 POLARIX trial" @default.
• W4315473447 doi "https://doi.org/10.1182/blood.2022017734" @default.
• W4315473447 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36626583" @default.
• W4315473447 hasPublicationYear "2023" @default.
• W4315473447 type Work @default.
• W4315473447 citedByCount "2" @default.
• W4315473447 countsByYear W43154734472023 @default.
• W4315473447 crossrefType "journal-article" @default.
• W4315473447 hasAuthorship W4315473447A5000406804 @default.
• W4315473447 hasAuthorship W4315473447A5000432967 @default.
• W4315473447 hasAuthorship W4315473447A5001892235 @default.
• W4315473447 hasAuthorship W4315473447A5002329460 @default.
• W4315473447 hasAuthorship W4315473447A5003078312 @default.
• W4315473447 hasAuthorship W4315473447A5003656187 @default.
• W4315473447 hasAuthorship W4315473447A5004358361 @default.
• W4315473447 hasAuthorship W4315473447A5004550999 @default.
• W4315473447 hasAuthorship W4315473447A5006621752 @default.
• W4315473447 hasAuthorship W4315473447A5006822602 @default.
• W4315473447 hasAuthorship W4315473447A5010046270 @default.
• W4315473447 hasAuthorship W4315473447A5012675709 @default.
• W4315473447 hasAuthorship W4315473447A5013007045 @default.
• W4315473447 hasAuthorship W4315473447A5014614303 @default.
• W4315473447 hasAuthorship W4315473447A5018450513 @default.
• W4315473447 hasAuthorship W4315473447A5019218337 @default.
• W4315473447 hasAuthorship W4315473447A5019659276 @default.
• W4315473447 hasAuthorship W4315473447A5026641386 @default.
• W4315473447 hasAuthorship W4315473447A5028596968 @default.
• W4315473447 hasAuthorship W4315473447A5034694073 @default.
• W4315473447 hasAuthorship W4315473447A5047640708 @default.
• W4315473447 hasAuthorship W4315473447A5058521062 @default.
• W4315473447 hasAuthorship W4315473447A5061466414 @default.
• W4315473447 hasAuthorship W4315473447A5063300954 @default.
• W4315473447 hasAuthorship W4315473447A5064319201 @default.
• W4315473447 hasAuthorship W4315473447A5072617729 @default.
• W4315473447 hasAuthorship W4315473447A5076088179 @default.
• W4315473447 hasAuthorship W4315473447A5076570353 @default.
• W4315473447 hasAuthorship W4315473447A5084148942 @default.
• W4315473447 hasAuthorship W4315473447A5087038882 @default.
• W4315473447 hasAuthorship W4315473447A5090013547 @default.
• W4315473447 hasBestOaLocation W43154734471 @default.
• W4315473447 hasConcept C126322002 @default.
• W4315473447 hasConcept C141071460 @default.
• W4315473447 hasConcept C143998085 @default.
• W4315473447 hasConcept C197934379 @default.
• W4315473447 hasConcept C207103383 @default.
• W4315473447 hasConcept C2776694085 @default.
• W4315473447 hasConcept C2776755627 @default.
• W4315473447 hasConcept C2778720950 @default.
• W4315473447 hasConcept C2779338263 @default.
• W4315473447 hasConcept C2779429289 @default.
• W4315473447 hasConcept C2779725641 @default.
• W4315473447 hasConcept C2780653079 @default.
• W4315473447 hasConcept C2908647359 @default.
• W4315473447 hasConcept C44249647 @default.
• W4315473447 hasConcept C71924100 @default.
• W4315473447 hasConcept C90924648 @default.
• W4315473447 hasConcept C99454951 @default.
• W4315473447 hasConceptScore W4315473447C126322002 @default.
• W4315473447 hasConceptScore W4315473447C141071460 @default.
• W4315473447 hasConceptScore W4315473447C143998085 @default.
• W4315473447 hasConceptScore W4315473447C197934379 @default.
• W4315473447 hasConceptScore W4315473447C207103383 @default.
• W4315473447 hasConceptScore W4315473447C2776694085 @default.
• W4315473447 hasConceptScore W4315473447C2776755627 @default.
• W4315473447 hasConceptScore W4315473447C2778720950 @default.

• next